

ADEOS - Adherence evaluation of osteoporosis treatment

Head :Leclerc-Zwirn Christel, Laboratoire GSK

Last update : 01/01/2018 | Version : 1 | ID : 151

General	
Identification	
Detailed name	Adherence evaluation of osteoporosis treatment
Sign or acronym	ADEOS
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL : 770334
General Aspects	
Medical area	Rheumatology
Others (details)	Osteoporosis
Keywords	adhesion, tool, osteoporosis, observance, persistence
Scientific investigator(s) (Contact)	
Name of the director	Leclerc-Zwirn
Surname	Christel
Phone	+33 (0)1 39 17 86 96
Email	christel.c.leclerc-zwirn@gsk.com
Unit	Laboratoire GSK
Collaborations	
Funding	
Funding status	Private
Details	GSK laboratory
Governance of the database	

Sponsor(s) or organisation(s) responsible	Laboratoire GSK
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health care professionals
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	The source population (potentially eligible patients) is represented by the patients wherein a treatment for osteoporosis from among those defined in the inclusion criteria is prescribed during a spontaneous consultation of a general practitioner who has accepted to participate in the study. Participating doctors will systematically and consecutively include up to 3 patients who meet all of the eligibility criteria.
Database objective	
Main objective	Finalize and validate a self-administered instrument developed to evaluate adherence to the treatment of postmenopausal osteoporosis
Inclusion criteria	Woman; Over the age of 50 years; Patient to whom has been prescribed one of the following osteoporosis treatments in the six months prior to the inclusion starting date: bisphosphonates, selective estrogen receptor modulators (SERM), or strontium ranelate; Patient fluent in French and who has the cognitive and functional ability required to complete the self-questionnaires included in the study on their own;

Informed patient who has given their oral consent to participate in this study

Population type

Age
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered
Sick population

Gender
Woman

Geography area
National

Detail of the geography area
France

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)
2008

Date of last collection (YYYY or MM/YYYY)
2008

Size of the database

Size of the database (number of individuals)
< 500 individuals

Details of the number of individuals
350

Data

Database activity
Data collection completed

Type of data collected
Clinical data
Declarative data

Clinical data (detail)
Direct physical measures
Medical registration

Declarative data (detail)
Paper self-questionnaire

Presence of a biobank
No

Health parameters studied
Others

Other (detail)
adherence, compliance, persistence

Procedures	
Data collection method	Two types of data will be collected during the study. Data concerning the subjective considerations of the patients will be collected via self-questionnaires. Medical data will be collected through computerized medical collection ("questions on the screen") completed by the doctor.
Participant monitoring	No
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Publications: Breuil et al. Osteoporosis International. 2011
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only